Multiple system atrophy-the nature ofthe beast describing, two sporadic cases, were the first to introduce the term olivopontocerebellar atrophy (OPCA). Their first case was a woman of 52 years, the second a man of 42. Both developed ataxia, dysarthria, akinesia, rigidity and brisk leg reflexes. The woman developed incontinence of urine, and died after 3 years. The man developed tremor, incontinence ofurine, and probable symptomatic postural hypotension ("etourdissements"). Pathological examination of the first case revealed atrophy of the olives, pons and cerebellum. The substantia nigra and striatum were not examined, or at least not commented upon.
The next piece of the jigsaw was a paper by Bradbury and Eggleston in the American Heart Journalin 1925 entitled "Postural hypotension. A report of three cases".3 Here they described three male subjects whose symptoms began in middle life (aged 36, 47, 60 years) and who were seen after from 3 to 7 years of illness. Common to all three were symptomatic postural hypotension and anhidrosis. Patient 1 had additional impotence and constipation, cases 2 and 3 had unequal pupils and brisk leg reflexes, and case 3 had bilateral extensor plantar responses. Two patients died suddenly, and two years later4 they reported postmortem findings in one of these cases, but unfortunately the central nervous system was not examined. Over subsequent years, a number of authors began to recognise in some patients a clinical association between orthostatic hypotension and disease of the central nervous system, especially Parkinsonism. 56 The case of Langston5 was a man of 56 with a 7 year history of autonomic failure followed by Parkinsonism with antecollis, husky and uncontrollable speech, "peculiar involuntary movements resembling laughter" and emotionalism. Young's patient,6 a man of43, also had a 5 year history comprising autonomic failure, Parkinsonism, an unsteady, staggering gait and a husky voice. A left vocal cord paresis was noted.
The next developments took place in 1960. It is important to remember that this was before the levodopa era, and to keep in mind that today the degree of clinical response to levodopa is the single most useful diagnostic pointer in the differential diagnosis of Parkinsonism. Shy and Drager in 19607 described "A neurological syndrome associated with orthostatic hypotension". They had seen four cases, and reported two in detail, with pathology in one. Both were male. Case 1 began at age 39, and was seen at age 46 after 7 years of disease. Case 2 began at age 49, and died at age 551 after 6j years of disease. Both had marked autonomic failure, slurred speech, impaired co-ordination and distal muscle wasting. Both had tremor at rest affecting the hands, and case 1 also had tremor on movement. Case 1 had pyramidal signs, case 2 equivocal plantar responses and fasciculations. Both are said to have had external ocular muscle 79 paresis, but in case 1 this was a slight exophoria and in case 2 "inability to converge and weakness of the medial rectus muscle bilaterally". Both had reduced facial expression, case 2 noted slowness ofmovements, and rigidity was present in both.
Post-mortem examination ofcase 2 showed cell loss and/or gliosis in many areas, but most marked in the caudate, substantia nigra, olives, locus coeruleus, cerebellum and intermediolateral cell columns of the spinal cord; the putamen, globus pallidus and pons were also affected. In the introduction, the authors defined the full syndrome as comprising the following features: orthostatic hypotension, urinary and rectal incontinence, loss of sweating, iris atrophy, external ocular palsies, rigidity, tremor, loss of associated movements, impotence, the findings of an atonic bladder and loss of the rectal sphincter tone, fasciculations*, wasting of distal muscles, evidence of a neuropathic lesion in the electromyogram that suggests involvement of the anterior horn cells*, and the finding of a neuropathic lesion in the muscle biopsy. Items with an asterisk* were found only in case 2. It is of interest to note that neither cerebellar nor pyramidal signs appear in this definition of the full syndrome.
In the previous year Van der Eecken, Adams and van Bogaert had made a brief presentation to the American Association of Neuropathologists entitled "Striopallidal-nigral degeneration. An hitherto undescribed lesion in paralysis agitans" which was published in 196O.' They called attention to the finding of pronounced shrinkage and brownish discoloration of parts of the putamen and globus pallidus as well as the usual depigmentation of the substantia nigra. Microscopically, one of the most striking lesions was the virtual disappearance ofthe small cells ofboth caudate and putamen.
The same authors (Adams et a) in 1961 published a longer paper entitled: "Degenerescences nigro-striees et cerebello-nigro-striees".9 In it, they gave clinical and pathological details of 3 patients (2 M, 1 F) with sporadic disease. All had an akinetic-rigid syndrome with tremor (slight action, slight rest, and 4-5 Hz respectively). Reflexes were brisk in all three, plantars extensor in case 2, and there was ataxia and intention tremor in case 3. Cases 1 and 3 had severe speech disturbance, case 1 had blackouts and impotence, and case 2 double incontinence. The pathology involved not only striatum and nigra, but also olives and cerebellum in all three cases, with additional pontine lesions in cases 1 and 3. Case 2 also had Lewy bodies in substantia nigra. Neither clinically nor pathologically, therefore, was striatonigral degeneration a pure and restricted entity resulting from pathology of these structures alone.
It seems surprising that accounts of striatal patho- In their review of striatonigral degeneration, '5 Adams and Salam-Adams excellently summarised the clinical heterogeneity of MSA: "SND, OPCD and SDS symptomatically can occur singly or combined in all possible ways. Each of the clinical syndromes may mark the beginning of the disease, but if the patient survives for many years the appearance of the other two syndromes can be predicted". Unfortunately, the review ends by proposing the term "striatonigralcerebellar-autonomic degeneration"! An additional problem in clinical assessment of these patients is that it can be well nigh impossible to state whether a patient with severe Parkinsonism incorporating marked dysarthria and postural instability has cerebellar signs, and vice-versa. Moreover, the increase in tendon jerks in a rigid limb and the occasional presence of a "striatal toe" or "dystonic foot response" makes it difficult to recognise pyramidal signs in extrapyramidal disease.
One of the particular features of multiple system atrophy is that it sits astride a number of disciplines and sub-specialities. Part of the difficulty experienced by many physicians in conceptually getting to grips with the condition stems from precisely this characteristic. For me, the analogy of the blindfolded men examining different parts of an elephant and coming away with different impressions of the nature of the beast is an excellent one. Much of what has been written about MSA has been written by doctors with a special interest in the autonomic nervous system, for obvious reasons since the disease offers such an excellent model for its understanding. However, prominent autonomic symptoms may be absent in very many patients early in the disease, and indeed throughout its course in some subjects. My own perspective of MSA, viewing from a Parkinson's disease clinic, is of an irregular lumpy iceberg. Above the surface is one mini-iceberg of pure autonomic failure, and another of OPCA. Beneath the waves lie the bulk of MSA cases, these "striatonigral" variants who, unrecognised, swell the ranks of Parkinson's disease clinics, participating in drug trials and transplantation programmes. The gradual recognition of their existence owes itself to three factors. Firstly, exposure to many Parkinsonian patients makes it easier to recognise what is typical and hence what is atypical. Secondly, the pathological proof in those cases clinically recognised as MSA who have had a post-mortem examination helps to confirm and hence validate clinical diagnostic criteria. And thirdly the 81 picture emerging from large post-mortem series of Parkinsonian brains is that cases of MSA are more common than previously thought, and also frequently mis-diagnosed in life.
Before examining larger and more recent series, it is salutary to consider a paper from Tygstrup and N0rholm'6 in 1963, prior to the introduction of levodopa. They reported the necropsy results in 12 patients from a larger series who had died from 1 week to 4 years after a stereotactic operation for Parkinsonism. All showed degeneration of substantia nigra. However, only five had Lewy bodies: two of the remaining seven had multiple system atrophy. Takei and Mirra'3 found MSA in 7 9% of 89 brains of patients with Parkinsonism. This led them to feel "that striatonigral degeneration is not an extremely rare disease, but that this group constitutes a significant proportion of Parkinsonian cases." Duvoisin, largely on clinical grounds, estimated that in his own consulting practice OPCA accounts for 5 to 6% of all Parkinsonism. ' Brain' entitled "The syndrome ofprimary orthostatic hypotension") developed somatic neurological features 31 years after the onset ofpure dysautonomia and, at necropsy, had classic pathological findings of "the Shy-Drager syndrome"." Does Shy-Drager syndrome refer only to the full clinical syndrome they Quinn described (which I have never seen), or to the pathology which revealed atrophy ofmultiple systems? My own view is that, whilst acknowledging their major contribution in recognising the somatic neurological features associated with some cases of autonomic failure and in describing the underlying pathology, we should cease to use the term Shy-Drager syndrome since its meaning has become so imprecise. If the term is to be retained at all, then I think it should refer to the clinical picture of Parkinsonism with autonomic failureplus features incompatible with IPD, viz lack of response to levodopa, or the presence of pyramidal or cerebellar signs.
Progressive autonomic failure (PAF) is a term that gradually supplanted idiopathic orthostatic hypotension. More recently, terminology has again changed, so that PAF now stands for pure autonomic failure. 23 But how is autonomic failure defined? All physicians recognise "barn-door" autonomic failure when confronted with it, but where does mild autonomic dysfunction (as seen in many patients with Parkinson's disease and also some normal subject) end and autonomic failure begin? The autonomic research community have not yet agreed universal criteria for a diagnosis of autonomic failure.2' There are certainly a number of tests of autonomic function which have been validated in control populations, and for which it is possible to state that an individual lies outside the normal range, or one or two standard deviations from the mean. But how many of these single tests need to be how abnormal before autonomic failure is diagnosed, and how can the diagnosis be made in less severe cases without recourse to an autonomic function laboratory? McLeod and Tuck' require abnormal results in two or more of the following tests: the response of blood pressure to change in posture and isometric contraction, heart rate response to standing, variation in heart rate with respiration, Valsalva ratio, sweat tests and plasma noradrenaline measurements. Moreover, none of the usual tests of autonomic function can distinguish between autonomic failure as part of MSA and as part of Lewy body disease, although dynamic tests of circulating noradrenaline concentrations may help (see below).
Even the definition of orthostatic hypotension varies greatly from one group to another (table 1).132
Beyond the question of what numerical drop in systolic/diastolic/mean blood pressure on assuming the erect posture is significant, other confounding factors abound. How long should the subject be supine before standing? Should the patient's blood pressure be recorded after active standing (some MSA patients may be unable to do this because of their motor disability) or using a tilt-table (the latter will give a different pulse and blood pressure profile),33 and for how long? Should Korotkow phase IV or V be used?
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Multiple system atrophy-the nature of the beast When one turns to OPCA, the genetic picture is more complex. Among adult-onset cases of OPCA, rather less than half seem to be inherited, as a dominant trait; the remainder have apparently arisen sporadically. Neither clinical features alone nor pathology may suffice to differentiate between the inherited and the sporadic form in an individual case, although group differences exist. Thus, in Berciano's 1982 review53 of 117 cases of pathologically confirmed OPCA, 39% of 54 familial cases showed Parkinsonism (55% of 63 sporadic cases), 50% pyramidal signs (46%), 96% cerebellar signs (87%) and 39% sphincter disturbance (48%). Pathologically, in addition to involvement of olives, pons and cerebellum, striatum was affected in 22% of familial cases (38% of sporadic) and substantia nigra in 46% (48%). Thus, neither Parkinsonian features nor sphincter disturbance, and neither striatal nor nigral pathology, clearly differentiates between familial and sporadic cases of OPCA. However, mean age of onset in hereditary cases is earlier than in sporadic cases (28 years versus 49 years in the clinicopathological study of Berciano53; 39 years versus 49 years in the clinical Quinn study of Harding4). Moreover, mean disease duration to death in familial cases was 14-9 years, and in sporadic cases was 6-3 years. 53 In the clinical study of Harding' on 36 living sporadic cases of late onset cerebellar ataxia, mean duration of symptoms was 12-5 years. Only three (8%) patients had impassive facies, but no other extrapyramidal features. Nine patients (25%) had urinary symptoms. This series clearly differs from what we recognise as MSA, partly because only cerebellar ataxia was needed for inclusion, and perhaps partly because, in an effort to exclude cases with paraneoplastic cerebellar degeneration, patients with a subacute course or a disease duration of less than two years were excluded. Ophthalmoplegia was more frequent, and pigmentary retinal degeneration and optic atrophy only found, in familial cases.5' Since the predominantly striatonigral variant of MSA is sporadic, it seems appropriate to include in the rubric of MSA only sporadic cases of OPCA (although this restriction would be at variance with the wider usage of the term by Oppenheimer himself to include familial OPCA). Moreover, to be considered as clinically probable cases of MSA, they should also display either Parkinsonian features or autonomic failure, or both.
Neuropathological examination of the brain and spinal cord cannot at present distinguish between many cases of familial OPCA and sporadic cases of MSA, although the value of intermediolateral column cell counts in this respect has not been fully assessed.
Should this deter one from separating such cases? I think not. A myocardial infarct due to coronary atherosclerosis may look the same in someone with familial hypercholesterolaemia as in a heavy eater and smoker, yet the ultimate cause is different: on the one hand genetic, on the other acquired. It should not surprise us that a similar or even an identical pathological picture should develop via a common mechanism triggered by different root causes, one genetic and one perhaps acquired.
A number of MSA subjects may display abnormal eye movements. Most commonly, this consists of impaired or absent convergence, hypometric voluntary saccades and/or saccadic pursuit, and sometimes a supranuclear gaze palsy for up (and rarely down) gaze.55 Indeed, MSA is one of a number of causes of the clinical picture of progressive supranuclear palsy, which is often erroneously taken to be synonymous with Steele-Richardson-Olszewski disease. Thus, a number of cases of MSA would fulfil the clinical diagnostic criteria for Steele-Richardson disease proposed by both Golbe et al56 and Lees.5" Because of the potential for confusion between the two diseases, I would propose that a predominant downgaze paresis should constitute an exclusion criterion for the clinical diagnosis of MSA. On the basis of the above considerations, and following the proposals of groups formulating diagnostic criteria for multiple sclerosis' and for Alzheimer's disease,57 I propose the diagnostic classification set out in table 2. Undoubtedly this will need further modification in the future, particularly in regard to the definition of autonomic failure, and also in the light of pathological verification of cases fulfilling these diagnostic criteria. Moreover, this clinical diagnostic schema mirrors the drawbacks considered above, in that it fails to exclude cases of Steele-Richardson disease not yet displaying a predominant downgaze paresis.
"Redflags" ( of Parkinsonism may be over-represented.
Rapid clinical deterioration despite dopaminergic treatment is also highly suspicious. Indeed, many physicians recognise this, and only consider MSA in Parkinsonian patients with cerebellar features or pyramidal signs together with profound autonomic failure who deteriorate towards death within 5 or 6 years. Yet a number of cases of MSA survive 10 years or longer after the onset ofclinical symptoms or signs, and may never develop cerebellar or pyramidal signs. Failure to recognise this leads to a self-fulfilling prophecy whereby MSA cases with longer disease progression are not diagnosed as such in life. Similarly, failure to recognise the unusual nature of the case makes a post-mortem examination less likely to be sought.
Dating the onset ofthe disease is also problematical. Should one take the first sign of relatively non-specific impotence or sphincter disturbance, or date disease onset only from the onset of symptomatic postural hypotension or of the first motor symptoms and signs? Indeed, do any of these features in fact correspond to the actual onset of the disease process? There is now evidence to suggest that the onset of IPD 62 Computed tomographic (CT) scanning appears to be of only limited usefulness in the diagnosis of MSA. In subjects with a predominantly cerebellar presentation, cerebellar and/or brainstem atrophy may be seen, but since this is also seen in many familial cases of adult onset cerebellar atrophy this finding may not help in differential diagnosis. Among cases presenting a predominantly, or a pure, Parkinsonian syndrome the CT scan is usually normal. In only a minority of cases will the scan demonstrate clear atrophy of posterior fossa structures. Striatal CT images are normal in all forms of MSA.
Magnetic resonance imaging, however, may well prove useful in demonstrating striatal pathology in MSA, and its absence in IPD. Early studies using 1 5 tesla T2 weighted images suggested that cases of "Parkinson's disease" with rapid progression and poor response to treatment showed altered signal particularly in putamen, and it was proposed this might be due to abnormal deposition of iron in this structure. The debate over iron content of the putaminal pigments63 and its relationship to the MRI images continues unresolved at present. However, whatever the ultimate cause of the altered signal, it is beginning to look as if MRI scanning can detect the putaminal pathology so characteristic of striatonigral cases of MSA, thus differentiating them from IPD."" Positron emission tomography (PET) scans ofMSA patients have so far been few in number. It comes as no surprise that '8F-fluorodopa scans show low concentration of activity in striatum, as in IPD.6" The most modem scanners with sufficient resolution also demonstrate a lower caudate uptake in MSA subjects in contrast to relatively preserved caudate uptake in IPD.' However, it is likely that measures of postsynaptic function will prove more useful in differentiating between MSA and IPD, so that the results of "C-raclopride studies are awaited with interest. If these scans can demonstrate clear and unequivocal differences, and if a dopamine receptor ligand can be developed for SPET studies, then SPET scanning may emerge as a useful diagnostic tool.
Electrophysiological Treatment Sadly, the treatment of MSA is most disappointing. Levodopa preparations may transiently give useful improvement, but often either cause no improvement, or give rise to intolerable nausea and vomiting and/or symptomatic postural hypotension." However, it should be realised that some patients who seem not to be responding to levodopa can still deteriorate significantly when the drug is withdrawn. Head-up tilt of the bed at night, elastic support stockings, fluorocortisone and/or indomethacin, caffeine, DDAVP or atrial pacing may help cardiovascular problems.24" Anticholinergics can reduce urinary frequency (but may precipitate retention). Retention with overflow, or incomplete bladder emptying with infections, can be managed with intermittent self-catheterisation (if hand mobility permits) or indwelling suprapubic or urethral catheterisation. High fibre diet, bulk laxatives, suppositories or enemas may be needed for constipation. Tracheostomy for intermittent respiratory stridor (especially at night) must be considered with the utmost care. It may only cruelly prolong a precarious existence before inevitable death. Similarly, cricopharyngeal myotomy or gastrostomy in patients with severe dysphagia is seldom, if ever, indicated. The paramedical specialities of physiotherapy, occupational therapy, speech therapy (often directed at swallowing problems and communication aids rather than improving speech per se) and social work often are of much more practical use than anything the physician can offer. With their grave prognosis and their lack ofresponse to levodopa, these patients are, to my mind, more in need of a breakthrough in neuronal implant treatment than those with idiopathic Parkinson's disease. If embryonic nigral implants can be shown to work in IPD, then logically the next patient groups to be offered (this time striatal) implant treatment should be those with MSA.
We desperately need better diagnosis of MSA if we are to seek the cause, and hence a preventive or retardant treatment, for this terrible affliction. In the meantime, we need to draw on all our skills and compassion to help and comfort those who are struck by this disease. 
